Expand TRDA Menu
TRDA MENU

TRDA Latest Press Releases

-- June 2, 2026 --

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study Globe Newswire 7:00 AM

-- June 1, 2026 --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- May 26, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA Globe Newswire 5:33 PM

-- May 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA Globe Newswire 5:25 PM

-- May 18, 2026 --

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC Globe Newswire 8:00 AM

-- May 17, 2026 --

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 9:55 PM

-- May 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PRNewswire 10:30 PM

-- May 11, 2026 --

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 10:40 AM

-- May 7, 2026 --

Entrada Therapeutics Reports First Quarter 2026 Financial Results Globe Newswire 7:10 AM
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study Globe Newswire 7:00 AM

-- May 6, 2026 --

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 Globe Newswire 4:30 PM

-- March 2, 2026 --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 26, 2026 --

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 7:00 AM

-- February 17, 2026 --

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study Globe Newswire 7:00 AM

-- February 4, 2026 --

Entrada Therapeutics to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes